Deutsche Bank maintains a 'hold' rating on Novo Nordisk with a price target of DKK290 after discussions with the company's head of R&D. Novo Nordisk is cautiously optimistic about its new obesity drug study, cagrisema RD11, which may outperform the previous RD4 trial that disappointed markets. The company is competing fiercely with Eli Lilly in the GLP-1 obesity and diabetes drug market, focusing on next-generation therapies and oral formulations. Despite some positive outlook, Deutsche Bank sees limited upside potential for Novo Nordisk shares currently trading just below the target price.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
